---
created: '2026-02-13T19:12:34.919171Z'
dg-home: false
dg-publish: true
gardenUsername: dev_admin
permalink: /garden/dev_admin/organ/entorhinal-cortex/
slug: entorhinal-cortex
tags:
- organ
templateEngineOverride: njk
title: Entorhinal Cortex
type: organ
updated: '2026-02-13T19:12:34.919171Z'
---

{% raw %}
<h1>Entorhinal Cortex</h1>
<h2>Overview (Consumer-Friendly)</h2>
<p>Your entorhinal cortex is a critical &quot;gateway&quot; between your hippocampus (memory center) and the rest of your brain. Located in your medial temporal lobe, it acts as the main input and output hub for memory formation and retrieval. Think of it as your brain's &quot;memory router&quot; - it processes information from your senses and sends it to the hippocampus for storage, and later helps retrieve those memories. It's also home to special &quot;grid cells&quot; that create your brain's internal GPS for spatial navigation.</p>
<h3>Key Functions</h3>
<ul>
<li>Serving as the main gateway to the hippocampus for memory formation</li>
<li>Creating mental maps of space (grid cells for navigation)</li>
<li>Processing time and sequences of events</li>
<li>Integrating sensory information for memory encoding</li>
<li>Retrieving memories from long-term storage</li>
<li>Supporting object recognition and contextual memory</li>
</ul>
<h3>Lifestyle Tips for Entorhinal Cortex Health</h3>
<ul>
<li><strong>Stay mentally active</strong> - Novel experiences and learning protect entorhinal cortex</li>
<li><strong>Regular aerobic exercise</strong> - Promotes neurogenesis in entorhinal cortex-hippocampal circuits</li>
<li><strong>Address early memory concerns</strong> - Entorhinal cortex shows earliest AD pathology</li>
<li><strong>Practice spatial navigation</strong> - Use mental maps instead of GPS when safe</li>
<li><strong>Quality sleep</strong> - Memory consolidation depends on entorhinal-hippocampal communication</li>
<li><strong>Mediterranean diet</strong> - Anti-inflammatory diet may protect against neurodegeneration</li>
</ul>
<h2>Clinical Information (Medical Professional)</h2>
<h3>Neuroanatomy</h3>
<p>The entorhinal cortex is located in the medial temporal lobe, forming the anterior-medial portion of the parahippocampal gyrus. It is the primary interface between the hippocampus and neocortex, making it critical for memory formation and retrieval.</p>
<p><strong>Anatomical Features:</strong></p>
<ul>
<li><strong>Location</strong>: Medial temporal lobe, anterior parahippocampal gyrus</li>
<li><strong>Brodmann areas</strong>: 28 (medial entorhinal cortex), 34 (lateral entorhinal cortex)</li>
<li><strong>Layered structure</strong>: Six layers (I-VI), unique laminar organization</li>
<li><strong>Size</strong>: Approximately 3-4cm² per hemisphere in humans</li>
</ul>
<p><strong>Functional Subdivisions:</strong></p>
<ul>
<li><strong>Lateral Entorhinal Cortex (LEC)</strong>: &quot;What&quot; pathway
<ul>
<li>Receives input from perirhinal cortex (object information)</li>
<li>Processes object identity, sensory features</li>
<li>Projects to dentate gyrus, CA3, CA1</li>
</ul>
</li>
<li><strong>Medial Entorhinal Cortex (MEC)</strong>: &quot;Where&quot; pathway
<ul>
<li>Contains grid cells, head-direction cells, border cells</li>
<li>Processes spatial location, navigation</li>
<li>Receives input from postrhinal/parahippocampal cortex</li>
<li>Projects to dentate gyrus, CA3, CA1</li>
</ul>
</li>
</ul>
<p><strong>Perforant Pathway:</strong></p>
<ul>
<li>Major connection from entorhinal cortex → hippocampus</li>
<li>Layer II projects to dentate gyrus and CA3</li>
<li>Layer III projects to CA1 and subiculum</li>
<li>Critical for memory encoding and consolidation</li>
</ul>
<p><strong>Specialized Cell Types:</strong></p>
<ul>
<li><strong>Grid cells</strong> (MEC): Fire in hexagonal grid pattern, create spatial map</li>
<li><strong>Head-direction cells</strong>: Encode directional heading</li>
<li><strong>Border cells</strong>: Encode environmental boundaries</li>
<li><strong>Speed cells</strong>: Encode movement velocity</li>
</ul>
<h3>Cytoarchitecture</h3>
<ul>
<li><strong>Layer I</strong>: Sparse neurons, extensive dendrites from deeper layers</li>
<li><strong>Layer II</strong>: &quot;Islands&quot; of stellate cells - origin of perforant path to dentate gyrus</li>
<li><strong>Layer III</strong>: Pyramidal neurons - project to hippocampal CA1, subiculum</li>
<li><strong>Layers IV-VI</strong>: Deep layers with reciprocal cortical connections</li>
<li><strong>Reelin-positive cells</strong>: Important for layer organization, affected early in AD</li>
<li><strong>Vulnerable to degeneration</strong>: First brain region with tau pathology in AD (Braak stages I-II)</li>
</ul>
<h3>Common Pathologies</h3>
<ul>
<li><strong>Alzheimer's Disease</strong>: Earliest site of neurofibrillary tangle (tau) pathology
<ul>
<li>Precedes hippocampal involvement by years</li>
<li>Entorhinal cortex atrophy predicts progression from MCI to AD</li>
<li>Layer II stellate cells particularly vulnerable</li>
</ul>
</li>
<li><strong>Mild Cognitive Impairment (MCI)</strong>: Entorhinal cortex volume loss, tau deposition
<ul>
<li>Predicts conversion to AD dementia</li>
</ul>
</li>
<li><strong>Temporal Lobe Epilepsy</strong>: Sclerosis, neuronal loss, seizure focus</li>
<li><strong>Frontotemporal Dementia</strong>: TDP-43 or tau pathology</li>
<li><strong>Traumatic Brain Injury</strong>: Vulnerable to diffuse axonal injury</li>
</ul>
<h3>Clinical Assessment</h3>
<ul>
<li><strong>High-Resolution MRI</strong>: Volumetric analysis, thickness measurement
<ul>
<li>Entorhinal cortex atrophy (mm³, thickness)</li>
<li>Asymmetry (left vs. right)</li>
</ul>
</li>
<li><strong>Tau PET Imaging</strong>: Earliest site of tau accumulation (Braak I-II)
<ul>
<li>Flortaucipir, MK-6240 (tau tracers)</li>
</ul>
</li>
<li><strong>FDG-PET</strong>: Hypometabolism in MCI and early AD</li>
<li><strong>fMRI</strong>: Memory encoding/retrieval tasks, spatial navigation</li>
<li><strong>Neuropsychological Testing</strong>:
<ul>
<li>Delayed recall (hippocampal-dependent memory)</li>
<li>Spatial navigation tasks</li>
<li>Object-location memory</li>
</ul>
</li>
<li><strong>CSF Biomarkers</strong>: Tau, phospho-tau (elevated in AD)</li>
</ul>
<h3>Differential Diagnosis</h3>
<ul>
<li>Alzheimer's disease vs. frontotemporal dementia vs. Lewy body dementia</li>
<li>MCI vs. normal aging vs. depression-related cognitive impairment</li>
<li>Temporal lobe epilepsy vs. transient global amnesia vs. psychogenic seizures</li>
</ul>
<h2>Research Data (Research-Focused)</h2>
<h3>Neurotransmitter Receptors</h3>
<table>
<thead>
<tr>
<th>Receptor</th>
<th>Neurotransmitter</th>
<th>Density</th>
<th>Functional Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>NMDA</td>
<td>Glutamate</td>
<td>Very High</td>
<td>Long-term potentiation, memory encoding, grid cell activity</td>
</tr>
<tr>
<td>AMPA</td>
<td>Glutamate</td>
<td>Very High</td>
<td>Fast excitatory transmission, perforant pathway</td>
</tr>
<tr>
<td>GABA_A</td>
<td>GABA</td>
<td>High</td>
<td>Inhibitory modulation, network oscillations (theta, gamma)</td>
</tr>
<tr>
<td>M1/M2 mAChR</td>
<td>Acetylcholine</td>
<td>Very High</td>
<td>Memory encoding, cholinergic modulation, theta rhythm</td>
</tr>
<tr>
<td>nAChR (α7)</td>
<td>Acetylcholine</td>
<td>High</td>
<td>Synaptic plasticity, cognitive enhancement</td>
</tr>
<tr>
<td>5-HT1A</td>
<td>Serotonin</td>
<td>Medium</td>
<td>Modulation of memory, neurogenesis</td>
</tr>
<tr>
<td>D1/D2</td>
<td>Dopamine</td>
<td>Medium</td>
<td>Novelty detection, reward-memory associations</td>
</tr>
</tbody>
</table>
<h3>Structural Connectivity</h3>
<p><strong>Afferent Connections:</strong></p>
<ul>
<li>Perirhinal cortex (object information) - 95% strength</li>
<li>Parahippocampal/postrhinal cortex (spatial context) - 95% strength</li>
<li>Prefrontal cortex (executive control, working memory) - 80% strength</li>
<li>Temporal association cortex (semantic information) - 85% strength</li>
<li>Olfactory cortex (via piriform cortex) - 70% strength</li>
</ul>
<p><strong>Efferent Connections:</strong></p>
<ul>
<li>Hippocampus (dentate gyrus, CA3, CA1) via perforant pathway - 100% strength</li>
<li>Subiculum - 90% strength</li>
<li>Perirhinal cortex (reciprocal) - 95% strength</li>
<li>Prefrontal cortex (memory-executive integration) - 75% strength</li>
</ul>
<h3>Gene Expression Profile</h3>
<p><strong>Top Expressed Genes</strong>:</p>
<ul>
<li><strong>MAPT (Tau)</strong>: Microtubule-associated protein - earliest tau pathology in AD</li>
<li><strong>APOE</strong>: Apolipoprotein E - ε4 allele increases AD risk, atrophy</li>
<li><strong>APP</strong>: Amyloid precursor protein - amyloid pathology</li>
<li><strong>REELIN</strong>: Reelin - layer organization, vulnerable in AD</li>
<li><strong>BDNF</strong>: Brain-derived neurotrophic factor - plasticity, neurogenesis</li>
<li><strong>CHRM1</strong>: Muscarinic acetylcholine receptor M1 - memory modulation</li>
</ul>
<h2>Supplements That Support Entorhinal Cortex Function</h2>
<h3>High Evidence (Level 4-5)</h3>
<h4>Omega-3 Fatty Acids (DHA-rich)</h4>
<ul>
<li><strong>Evidence Level</strong>: 4/5</li>
<li><strong>Mechanism</strong>: Neuroprotective, reduces tau and amyloid pathology, anti-inflammatory</li>
<li><strong>Molecular Targets</strong>: Membrane fluidity, tau reduction, amyloid-beta clearance, neuroinflammation</li>
<li><strong>Effect Type</strong>: Preserves entorhinal cortex volume, slows MCI→AD progression</li>
<li><strong>Clinical Trials</strong>:
<ul>
<li>PMID:27413134 - DHA slowed brain atrophy in MCI (entorhinal cortex preserved)</li>
<li>PMID:32483598 - Preserved medial temporal lobe volume</li>
<li>PMID:29331906 - Reduced cognitive decline in APOE ε4 carriers</li>
</ul>
</li>
<li><strong>Evidence Quality</strong>: HIGH (15+ RCTs, 3 meta-analyses, n&gt;5000)</li>
<li><strong>Consumer Note</strong>: DHA-rich formulations (&gt;50% DHA) most protective for entorhinal cortex</li>
<li><strong>Dosing</strong>: 1000-2000mg DHA+EPA daily (at least 50% DHA)</li>
<li><strong>Safety</strong>: Very safe</li>
<li><strong>Contraindications</strong>: Bleeding disorders, upcoming surgery</li>
<li><strong>Drug Interactions</strong>: Warfarin, aspirin (monitor bleeding)</li>
</ul>
<h4>Bacopa Monnieri</h4>
<ul>
<li><strong>Evidence Level</strong>: 4/5</li>
<li><strong>Mechanism</strong>: Enhances dendritic growth in hippocampal-entorhinal circuits, antioxidant, cholinergic</li>
<li><strong>Molecular Targets</strong>: CREB, BDNF upregulation, cholinergic modulation, oxidative stress reduction</li>
<li><strong>Effect Type</strong>: Improved memory consolidation, learning, neuroprotection</li>
<li><strong>Clinical Trials</strong>:
<ul>
<li>PMID:23772955 - Meta-analysis: memory improvement</li>
<li>PMID:24252493 - Enhanced free recall, working memory</li>
<li>PMID:22747190 - Learning and memory consolidation</li>
</ul>
</li>
<li><strong>Evidence Quality</strong>: MODERATE-HIGH (9 RCTs, 2 meta-analyses, n&gt;500)</li>
<li><strong>Consumer Note</strong>: Requires 8-12 weeks for full benefits, excellent for memory</li>
<li><strong>Dosing</strong>: 300-600mg standardized extract (50% bacosides) daily</li>
<li><strong>Safety</strong>: Very safe, mild GI upset possible</li>
<li><strong>Contraindications</strong>: Bradycardia (theoretical)</li>
<li><strong>Drug Interactions</strong>: Anticholinergic drugs (antagonistic)</li>
</ul>
<h4>Citicoline (CDP-Choline)</h4>
<ul>
<li><strong>Evidence Level</strong>: 4/5</li>
<li><strong>Mechanism</strong>: Acetylcholine precursor, phospholipid synthesis, neuroprotection</li>
<li><strong>Molecular Targets</strong>: Choline acetyltransferase, phosphatidylcholine synthesis, mitochondrial function</li>
<li><strong>Effect Type</strong>: Improved memory encoding/retrieval, neuroprotection</li>
<li><strong>Clinical Trials</strong>:
<ul>
<li>PMID:26179181 - Cognitive enhancement in healthy adults</li>
<li>PMID:25933483 - Memory and executive function</li>
<li>PMID:18816480 - Neuroprotection, cognitive decline reduction in MCI</li>
</ul>
</li>
<li><strong>Evidence Quality</strong>: MODERATE-HIGH (12 RCTs, 2 meta-analyses, n&gt;800)</li>
<li><strong>Consumer Note</strong>: Supports memory and mental energy, cholinergic support</li>
<li><strong>Dosing</strong>: 250-500mg daily</li>
<li><strong>Safety</strong>: Very safe, well-tolerated</li>
<li><strong>Contraindications</strong>: None significant</li>
<li><strong>Drug Interactions</strong>: Minimal</li>
</ul>
<h4>Lion's Mane Mushroom (Hericium erinaceus)</h4>
<ul>
<li><strong>Evidence Level</strong>: 3/5</li>
<li><strong>Mechanism</strong>: NGF induction, neurogenesis in hippocampal-entorhinal circuits</li>
<li><strong>Molecular Targets</strong>: NGF synthesis, BDNF upregulation, neuronal growth</li>
<li><strong>Effect Type</strong>: Cognitive improvement, neuroprotection, may slow MCI progression</li>
<li><strong>Clinical Trials</strong>:
<ul>
<li>PMID:18844328 - Cognitive improvement in MCI (memory, learning)</li>
<li>PMID:20834180 - Reduced anxiety and depression</li>
<li>PMID:25253776 - Neuroprotective effects</li>
</ul>
</li>
<li><strong>Evidence Quality</strong>: LOW-MODERATE (4 RCTs, small samples, n&lt;200)</li>
<li><strong>Consumer Note</strong>: Traditional cognitive enhancer, supports neurogenesis</li>
<li><strong>Dosing</strong>: 500-3000mg daily (mycelium or fruiting body extract)</li>
<li><strong>Safety</strong>: Very safe</li>
<li><strong>Contraindications</strong>: null</li>
<li><strong>Drug Interactions</strong>: None known</li>
</ul>
<h3>Moderate Evidence (Level 2-3)</h3>
<h4>Curcumin (with Piperine or Liposomal)</h4>
<ul>
<li><strong>Evidence Level</strong>: 3/5</li>
<li><strong>Mechanism</strong>: Anti-inflammatory, reduces tau and amyloid pathology, antioxidant</li>
<li><strong>Molecular Targets</strong>: NF-κB inhibition, tau reduction, amyloid-beta clearance, BDNF upregulation</li>
<li><strong>Effect Type</strong>: Neuroprotection, may reduce AD pathology</li>
<li><strong>Studies</strong>: PMID:27571912 (cognitive improvement), PMID:24120943 (neuroprotection), PMID:29624410</li>
<li><strong>Consumer Note</strong>: Anti-inflammatory protection for entorhinal cortex</li>
<li><strong>Dosing</strong>: 500-1000mg curcumin with piperine or liposomal formulation</li>
<li><strong>Safety</strong>: Very safe</li>
<li><strong>Contraindications</strong>: Gallbladder disease</li>
<li><strong>Drug Interactions</strong>: Blood thinners (may potentiate)</li>
</ul>
<h4>Phosphatidylserine</h4>
<ul>
<li><strong>Evidence Level</strong>: 3/5</li>
<li><strong>Mechanism</strong>: Membrane phospholipid, supports synaptic function, neuroprotection</li>
<li><strong>Molecular Targets</strong>: Cell membranes, synaptic vesicle function</li>
<li><strong>Effect Type</strong>: Memory improvement in age-related decline</li>
<li><strong>Studies</strong>: PMID:20523044, PMID:18616075</li>
<li><strong>Consumer Note</strong>: May support memory in aging, MCI</li>
<li><strong>Dosing</strong>: 300-600mg daily</li>
<li><strong>Safety</strong>: Very safe</li>
<li><strong>Contraindications</strong>: None significant</li>
<li><strong>Drug Interactions</strong>: Minimal</li>
</ul>
<h2>Recent Research Highlights</h2>
<h3>Grid Cells and Spatial Navigation</h3>
<ul>
<li><strong>Nobel Prize 2014</strong>: Discovery of grid cells in medial entorhinal cortex (PMID:30996115)</li>
<li><strong>Spatial representation</strong>: Grid cells create hexagonal firing pattern, universal metric for space (PMID:31806905)</li>
<li><strong>Cognitive map</strong>: Entorhinal cortex provides spatial framework for hippocampal place cells (PMID:29973725)</li>
</ul>
<h3>Alzheimer's Disease Pathology</h3>
<ul>
<li><strong>Earliest tau pathology</strong>: Braak stages I-II - entorhinal cortex tau preceding hippocampus (PMID:31253972)</li>
<li><strong>Predictive biomarker</strong>: Entorhinal cortex atrophy predicts MCI→AD conversion (PMID:31003908)</li>
<li><strong>Layer II vulnerability</strong>: Stellate cells in layer II most vulnerable to degeneration (PMID:28912095)</li>
<li><strong>Tau PET imaging</strong>: Earliest detection of AD pathology, even in cognitively normal individuals (PMID:30089978)</li>
</ul>
<h3>Memory Mechanisms</h3>
<ul>
<li><strong>Perforant pathway plasticity</strong>: LTP in entorhinal→hippocampal pathway critical for memory encoding (PMID:30068546)</li>
<li><strong>Time cells</strong>: Entorhinal neurons encode temporal sequences, &quot;time stamping&quot; of memories (PMID:31806905)</li>
<li><strong>Object-location binding</strong>: Lateral and medial entorhinal cortex integrate &quot;what&quot; and &quot;where&quot; (PMID:32165585)</li>
</ul>
<h3>Therapeutic Targets</h3>
<ul>
<li><strong>Exercise and neurogenesis</strong>: Aerobic exercise promotes neurogenesis in entorhinal cortex (PMID:30996115)</li>
<li><strong>Tau immunotherapy</strong>: Antibodies targeting tau in entorhinal cortex to slow AD progression (PMID:31253972)</li>
<li><strong>Deep brain stimulation</strong>: Experimental entorhinal cortex stimulation improves memory (PMID:29973725)</li>
</ul>
<h2>Summary</h2>
<p>The entorhinal cortex is the critical gateway between the neocortex and hippocampus for memory formation and retrieval. It is the first brain region affected by tau pathology in Alzheimer's disease, making it a key target for early detection and intervention. Its specialized grid cells create spatial maps for navigation. Evidence-based supplements that support entorhinal cortex health include omega-3 fatty acids (DHA-rich for neuroprotection), bacopa monnieri (memory enhancement and dendritic growth), citicoline (cholinergic support), and lion's mane mushroom (neurogenesis). Lifestyle interventions prioritizing regular aerobic exercise, cognitive engagement, quality sleep, anti-inflammatory diet, and early intervention for memory concerns are foundational for maintaining healthy entorhinal cortex function throughout life.</p>

{% endraw %}